Wu et al. (2018) reported that treatment with osimertinib did not have a significant economic advantage for patients with advanced EGFR T790M mutation NSCLC after failure of first-line EGFR-TKIs compared with platinum-based chemotherapy in the United States and China, with both ICER values more than $220,000/QALY. On the contrary, other two studies recently published by Bertranou et al. and Guan et al. obtained different results (Bertranou et al., 2018; Guan et al., 2019). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.